Warsaw PLN

BIOTON S.A. (BIO.WA)

Compare
3.1800 -0.0050 (-0.16%)
At close: November 26 at 5:00 PM GMT+1
Loading Chart for BIO.WA
DELL
  • Previous Close 3.1850
  • Open 3.1600
  • Bid 3.1700 x --
  • Ask 3.0800 x --
  • Day's Range 3.1500 - 3.1800
  • 52 Week Range 3.0200 - 3.7750
  • Volume 21,947
  • Avg. Volume 23,566
  • Market Cap (intraday) 273.048M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0700
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. BIOTON S.A. was founded in 1989 and is based in Ozarów Mazowiecki, Poland.

www.bioton.pl

355

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News: BIO.WA

View More

Compare To: BIO.WA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BIO.WA

View More

Valuation Measures

Annual
As of 11/25/2024
  • Market Cap

    273.48M

  • Enterprise Value

    324.90M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.54

  • Price/Book (mrq)

    0.46

  • Enterprise Value/Revenue

    1.83

  • Enterprise Value/EBITDA

    8.07

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -3.27%

  • Return on Assets (ttm)

    -1.10%

  • Return on Equity (ttm)

    -0.97%

  • Revenue (ttm)

    177.6M

  • Net Income Avi to Common (ttm)

    -5.8M

  • Diluted EPS (ttm)

    -0.0700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    623k

  • Total Debt/Equity (mrq)

    8.74

  • Levered Free Cash Flow (ttm)

    7.52M

Research Analysis: BIO.WA

View More

Company Insights: BIO.WA

Research Reports: BIO.WA

View More

People Also Watch